The ranitidine impurity issue gave wings to the rising prescription of proton pump inhibitors (PPIs). The share of PPI prescriptions in the antiulcer agent market grew 30% in only 2 years after the drugs containing ranitidine – which used to occupy the largest share of the H2 receptor antagonists - were pulled from the market. Hanmi’s incrementally modified drug ‘Esomezol’ gained marked influence over the antiulcer drug market with the impurity issue and COVID-19 as momentum.

◆PPI prescriptions increase 5%...reaps benefits despite prolonged COVID-19 crisis

According to the pharmaceutical market research institution UBIST on the 4th, outpatient prescription of PPIs recorded &